JAX receives $1M from the Mark Foundation for Cancer Research

Funds will support research into immunotherapy response rates and side effects

Immunotherapy can be a crucial tool for patients undergoing cancer treatment, vastly improving outcomes for many whose conditions would otherwise be fatal. Unfortunately a subset of these patients develop toxic autoimmune side effects to immune checkpoint inhibitor (ICI) treatment. If we could predict those individuals at risk of developing particular adverse events, interventions for such complications could be initiated in the timeliest fashion.

A new $1 million grant from the Mark Foundation for Cancer Research presented to The Jackson Laboratory will fund research to study why these side effects sometimes occur and use the power of genetics to predict better outcomes for patients. Read more

Related Posts

UNE undergraduate receives BioME grant to study rare lobster larvae

A University of New England undergraduate student has received a $5,000 grant from the Bioscience Association of Maine (BioME) to fund...

23 May 2024

New initiative unites Maine’s innovators to bolster STEM research and workforce

An $8 million grant from the National Science Foundation will fund a four-year initiative led by the University of Maine to bolster STEM...

15 May 2024

Jackson Lab hires its first-ever chief scientific officer

Jackson Laboratory, based in Bar Harbor, has hired Mary Dickinson, a globally recognized geneticist, developmental biologist, and bioengineer, as executive vice...

13 May 2024